New Alzheimer's drug repairs DNA damage and reduces brain inflammation
Researchers at King's College London have identified that an existing drug, KCL-286, shows promise in treating Alzheimer's disease by repairing DNA damage and reducing inflammation. The drug has already passed Phase 1 safety trials, potentially accelerating the development timeline for a disease-modifying therapy.
Why it matters
Current Alzheimer's treatments have limited efficacy; a drug targeting early-stage biological mechanisms could fundamentally change the prognosis for millions of patients.
Researchers at King's College London have identified a promising new strategy for tackling Alzheimer's disease by targeting several of the disease's earliest biological changes at the same time. Their study found that KCL-286, an experimental drug originally developed for spinal cord injury that has already passed Phase 1 safety trials, reduced multiple hallmarks of Alzheimer's in a mouse model.
The article reports on scientific findings using neutral, descriptive language without political or social agenda.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in